XOMA Royalty Corporation
NGM: XOMAPLive Quote
📈 ZcoreAI Score
Our AI model analyzes XOMA Royalty Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get XOMAP Z-Score →About XOMA Royalty Corporation
Healthcare
Biotechnology
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
📊 Fundamental Analysis
XOMA Royalty Corporation demonstrates exceptional profitability, with a profit margin of 60.8%.
The company recently reported 57.9% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is 34.1%, which reflects exceptional capital efficiency.
At a current price of $26.47, XOMAP currently sits at the 30th percentile of its 52-week range (Range: $24.96 - $30.00).
💰 Valuation Insight
XOMAP is valued broadly in line with the sector at a PE of 26.44.
🏥 Financial Health
✅
Profit Margin
Excellent
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
✅
Return on Equity
Excellent
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$--
Trailing P/E
26.44
Forward P/E
--
Beta (5Y)
0.68
52W High
$30.00
52W Low
$24.96
Avg Volume
856
Day High
Day Low